Resources

Resources

BIOVECTRA offers a number of resources to help keep you up to date on industry trends and activities. Meet with us at events, follow us on LinkedIn, and explore the following resources for educational content.

On-Demand Webinar

For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L.[…]

Read More

White Paper

Large-scale single-use fermentation technology
using aerobic microbial expression systems offers an excellent complement to stainless steel bioreactors for clinical-to-commercial scale production of recombinant proteins. […]

Read More

Article

The development and production of mRNA therapeutics and vaccines requires expertise in both chemical synthesis and microbial fermentation.  […]

Read More

Interview

For the final interview of the Road to 50 States road trip campaign, Oliver Technow and Heather Delage of BIOVECTRA met with Nigel at CPhI in Milan to discuss the company’s unique capability to offer both small and large molecule biologic products to their clients. […]

Read More

White Paper

High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. The rich diversity of potent natural products necessitates a range of manufacturing demands.  […]

Read More

Article

BIOVECTRA’s Scott Doncaster, Neil Morrison, and Cameron Graham discuss the company’s addition of single-use fermenter technology […]

Read More

Article

Much of the innovation occurring in the pharmaceutical industry today is achieved by smaller pharma/biotech firms with limited commercial manufacturing experience […]

Read More

Article

The production of increasingly complex small molecule APIs is challenging drug makers. CDMOs with multiple capabilities are needed to develop efficient routes to synthesize these […]

Read More

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors